Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Home page Seeking Alpha - Power to Investors About Premium Explore Alpha Picks Home ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

Imfinzi is already approved for unresectable ... Sales momentum for the drug is still good, however, fuelled by a lengthening list of indications in other cancers, including most recently primary ...

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab ... and Bavencio have bladder cancer indications. In a statement, the big UK pharma ...

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early ...